Ask OQRO reads the filings behind this page and answers in plain words, with a link to each source.
Ask OQRO is part of OQRO Pro. Everything else on OQRO is free.
Only to see which pages are hard to use, so we can fix them. Nothing is used for ads, and what you type stays hidden (Microsoft Clarity, PostHog). Privacy Policy
The latest available 13F covers holdings as of Jun 30, 2026 (Q2 2026) and was filed Aug 14, 2026. Quarter-end snapshot, not a live trade.
Disclosed 13F value
$8.03B
sum of reported positions
Reported positions
72
Changes vs prior quarter
46
11 new · 12 exited
Filings on record
9
Q2 2026, Q1 2026, Q4 2025, Q3 2025, Q2 2025, Q1 2025, Q4 2024, Q3 2024, Q2 2024
Across 113 measured positions in 8 quarters, the typical new or larger position finished +2.4 pts against the S&P 500 and 56% finished ahead of it. For scale, across all 501 funds with a result: −2.2 pts typical, 44% ahead.
Measured on each position this fund reported as new or larger, from the first close after the filing became public, against the S&P 500, 90 days later. Sales are not scored. History, not a forecast; it shows what the stocks did, not what the fund knew.
Total value of the 13F each quarter. It moves with prices as well as with what the fund bought or sold, so a rise is not necessarily a purchase.
| Company | Shares | Value | Weight |
|---|---|---|---|
NUVALENT INC | 17.2M | $2.13B | 26.5% |
| 2.39M | $448M | 5.6% | |
| 963K | $323M | 4.0% | |
| 20.2M | $321M | 4.0% |
Comparison uses this manager's immediately preceding 13F-HR. Puts and calls are separate lines. Share counts drive classification; reported value also moves with price.Methodology
Change in the reported value against the quarter before.
Weights are within the disclosed 13F portfolio, for the ten largest lines.
| Q1 2026 | Q2 2026 | |
|---|---|---|
| Reported value | $7.18B | $8.03B |
| Positions | 73 | 72 |
| Biggest line | — | NUVALENT INC 27% |
| 4.9M | $315M | 3.9% |
| 457K | $248M | 3.1% |
| 8.14M | $235M | 2.9% |
| 5.01M | $194M | 2.4% |
| 6.87M | $189M | 2.3% |
| 11.6M | $187M | 2.3% |
| 3.92M | $168M | 2.1% |
| 1.98M | $157M | 2.0% |
| 1.45M | $152M | 1.9% |
| 15.1M | $151M | 1.9% |
| 4.26M | $145M | 1.8% |
| 4.52M | $133M | 1.7% |
| 4.19M | $131M | 1.6% |
| 11.5M | $120M | 1.5% |
| 3.38M | $117M | 1.5% |
| 1.39M | $113M | 1.4% |
| 1.13M | $110M | 1.4% |
| 35.6M | $109M | 1.4% |
| 3.96M | $107M | 1.3% |
| 2.71M | $101M | 1.3% |
| 1.62M | $97.5M | 1.2% |
Avalyn Pharma (AVLN)
731K shares
Odyssey Therapeutics (ODTX)
1.05M shares
Alamar Biosciences (ALMR)
600K shares
Chemed Corp. (CHE)
30K shares
Adagene (ADAG)
2.67M shares
Hemab Therapeutics Holdings (COAG)
275K shares
Mobia Medical (MOBI)
671K shares
Veracyte, Inc. (VCYT)
726K → 101K shares (−86%)
Mirum Pharmaceuticals (MIRM)
6,027 shares
ENHABIT INC
4.75M shares in Q1 2026
CATALYST PHARMACEUTICALS INC
3.94M shares in Q1 2026
DAY ONE BIOPHARMACEUTICALS I
3.72M shares in Q1 2026
Compass Therapeutics (CMPX)
3.61M shares in Q1 2026
Taysha Gene Therapies (TSHA)
2.72M shares in Q1 2026
Neurocrine Biosciences (NBIX)
610K shares in Q1 2026
Kymera Therapeutics (KYMR)
561K shares in Q1 2026
Cullinan Therapeutics (CGEM)
386K shares in Q1 2026
QUANTUM SI INC
333K shares in Q1 2026
BIOMX INC
131K shares in Q1 2026
Veradermics (MANE)
5,000 shares in Q1 2026
Myriad Genetics (MYGN)
505 shares in Q1 2026
